Ablative and Immunostimulatory Effects of Histotripsy Ablation in a Murine Osteosarcoma Model

dc.contributor.authorHay, Alayna N.en
dc.contributor.authorImran, Khan Mohammaden
dc.contributor.authorHendricks-Wenger, Alissaen
dc.contributor.authorGannon, Jessica M.en
dc.contributor.authorSereno, Jacquelineen
dc.contributor.authorSimon, Alexen
dc.contributor.authorLopez, Victor A.en
dc.contributor.authorCoutermarsh-Ott, Sherylen
dc.contributor.authorVlaisavljevich, Elien
dc.contributor.authorAllen, Irving C.en
dc.contributor.authorTuohy, Joanne L.en
dc.date.accessioned2023-10-27T13:35:04Zen
dc.date.available2023-10-27T13:35:04Zen
dc.date.issued2023-10-09en
dc.date.updated2023-10-27T10:26:57Zen
dc.description.abstract<i>Background</i>: Osteosarcoma (OS) is the most frequently occurring malignant bone tumor in humans, primarily affecting children and adolescents. Significant advancements in treatment options for OS have not occurred in the last several decades, and the prognosis remains grim with only a 70% rate of 5-year survival. The objective of this study was to investigate the focused ultrasound technique of histotripsy as a novel, noninvasive treatment option for OS. <i>Methods:</i> We utilized a heterotopic OS murine model to establish the feasibility of ablating OS tumors with histotripsy in a preclinical setting. We investigated the local immune response within the tumor microenvironment (TME) via immune cell phenotyping and gene expression analysis. <i>Findings:</i> We established the feasibility of ablating heterotopic OS tumors with ablation characterized microscopically by loss of cellular architecture in targeted regions of tumors. We observed greater populations of macrophages and dendritic cells within treated tumors and the upregulation of immune activating genes 72 h after histotripsy ablation. <i>Interpretation:</i> This study was the first to investigate histotripsy ablation for OS in a preclinical murine model, with results suggesting local immunomodulation within the TME. Our results support the continued investigation of histotripsy as a novel noninvasive treatment option for OS patients to improve clinical outcomes and patient prognosis.en
dc.description.versionPublished versionen
dc.format.mimetypeapplication/pdfen
dc.identifier.citationHay, A.N.; Imran, K.M.; Hendricks-Wenger, A.; Gannon, J.M.; Sereno, J.; Simon, A.; Lopez, V.A.; Coutermarsh-Ott, S.; Vlaisavljevich, E.; Allen, I.C.; Tuohy, J.L. Ablative and Immunostimulatory Effects of Histotripsy Ablation in a Murine Osteosarcoma Model. Biomedicines 2023, 11, 2737.en
dc.identifier.doihttps://doi.org/10.3390/biomedicines11102737en
dc.identifier.urihttp://hdl.handle.net/10919/116564en
dc.language.isoenen
dc.publisherMDPIen
dc.rightsCreative Commons Attribution 4.0 Internationalen
dc.rights.urihttp://creativecommons.org/licenses/by/4.0/en
dc.subjecttumor ablationen
dc.subjectfocused ultrasounden
dc.subjecttumor immunologyen
dc.subjectDLM8 cell lineen
dc.titleAblative and Immunostimulatory Effects of Histotripsy Ablation in a Murine Osteosarcoma Modelen
dc.title.serialBiomedicinesen
dc.typeArticle - Refereeden
dc.type.dcmitypeTexten

Files

Original bundle
Now showing 1 - 1 of 1
Loading...
Thumbnail Image
Name:
biomedicines-11-02737-v2.pdf
Size:
6.32 MB
Format:
Adobe Portable Document Format
License bundle
Now showing 1 - 1 of 1
Name:
license.txt
Size:
0 B
Format:
Item-specific license agreed upon to submission
Description: